World Library  
Flag as Inappropriate
Email this Article

Pneumocystis pneumonia

Article Id: WHEBN0007286863
Reproduction Date:

Title: Pneumocystis pneumonia  
Author: World Heritage Encyclopedia
Language: English
Subject: Pneumocystosis, Way Bandy, Pneumonia, Respiratory disease, Allergic bronchopulmonary aspergillosis
Collection: Fungal Diseases, Pneumonia
Publisher: World Heritage Encyclopedia

Pneumocystis pneumonia

Pneumocystis jirovecii pneumonia
Pneumocystis jirovecii cysts from bronchoalveolar lavage, stained with Toluidine blue O stain
Classification and external resources
Specialty Pulmonology
ICD-10 B20.6
ICD-9-CM 136.3
DiseasesDB 10160
MedlinePlus 000671
eMedicine med/1850
MeSH D011020

Pneumocystis pneumonia (PCP) is a form of pneumonia, caused by the yeast-like fungus Pneumocystis jirovecii.[1]

Pneumocystis pneumonia is not commonly found in the lungs of healthy people, but, being a source of opportunistic infection, it can cause a lung infection in people with a weak immune system. Pneumocystis pneumonia is especially seen in people with cancer undergoing chemotherapy, HIV/AIDS, and the use of medications that suppress the immune system.


  • Signs and symptoms 1
    • Disease course 1.1
  • Diagnosis 2
  • Prevention and treatment 3
  • Epidemiology 4
    • PCP and AIDS 4.1
  • Nomenclature 5
  • References 6

Signs and symptoms

Signs and symptoms of PCP include liver, spleen, and kidney), but only in a minority of cases.

Pneumothorax is a well-known complication of PCP.[2] An acute history of chest pain with breathlessness and diminished breath sounds is typical of pneumothorax.

Disease course

The risk of PCP increases when CD4 positive T-cell levels are less than 200 cells/μL. In these immunosuppressed individuals the manifestations of the infection are highly variable.[3] The disease attacks the interstitial, fibrous tissue of the lungs, with marked thickening of the alveolar septa and alveoli, leading to significant hypoxia which can be fatal if not treated aggressively. In this situation LDH levels increase and gas exchange is compromised. Oxygen is less able to diffuse into the blood, leading to hypoxia. Hypoxia, along with high arterial carbon dioxide (CO2) levels, stimulates hyper-ventilatory effort, thereby causing dyspnea (breathlessness).


X-ray of Pneumocystis jirovecii pneumonia. There is increased opacification (whiteness) in the lower lungs on both sides, characteristic of Pneumocystis pneumonia

The diagnosis can be confirmed by the characteristic appearance of the sputum or bronchio-alveolar lavage (lung rinse). Staining with toluidine blue, silver stain, periodic-acid schiff stain, or an immunofluorescence assay will show the characteristic cysts.[4] The cysts resemble crushed ping-pong balls and are present in aggregates of 2 to 8 (and not to be confused with Histoplasma or Cryptococcus, which typically do not form aggregates of spores or cells). A lung biopsy would show thickened alveolar septa with fluffy eosinophilic exudate in the alveoli. Both the thickened septa and the fluffy exudate contribute to dysfunctional diffusion capacity which is characteristic of this pneumonia.

Pneumocystis infection can also be diagnosed by immunofluorescent or histochemical staining of the specimen, and more recently by molecular analysis of polymerase chain reaction products comparing DNA samples. Notably, simple molecular detection of Pneumocystis jirovecii in lung fluids does not mean that a person has Pneumocystis pneumonia or infection by HIV. The fungus appears to be present in healthy individuals in the general population.[5]

Prevention and treatment

In immunocompromised patients, prophylaxis with co-trimoxazole (trimethoprim/sulfamethoxazole),[6] atovaquone, or regular pentamidine inhalations may help prevent PCP.

Antipneumocystic medication is used with concomitant steroids in order to avoid inflammation, which causes an exacerbation of symptoms about four days after treatment begins if steroids are not used. By far the most commonly used medication is trimethoprim/sulfamethoxazole, but some patients are unable to tolerate this treatment due to allergies. Other medications that are used, alone or in combination, include pentamidine, trimetrexate, dapsone, atovaquone, primaquine, pafuramidine maleate (under investigation), and clindamycin. Treatment is usually for a period of about 21 days.

Pentamidine is less often used as its major limitation is the high frequency of side effects. These include acute pancreatic inflammation, kidney failure, liver toxicity, decreased white blood cell count, rash, fever, and low blood sugar.


Pneumocystis jirovecii

The disease PCP is relatively rare in people with normal immune systems, but common among people with weakened bone marrow transplantation and after surgery.[8] Infections with Pneumocystis pneumonia are also common in infants with hyper IgM syndrome, an X-linked or autosomal recessive trait.

The causative organism of PCP is distributed worldwide[9] and Pneumocystis pneumonia has been described in all continents except Antarctica.[9] Greater than 75% of children are

  1. ^ a b Aliouat-Denis, C-M.; et al. (2008). "Pneumocystis species, co-evolution and pathogenic power". Infection, Genetics and Evolution 8 (5): 708–726.  
  2. ^ Kanne JP1, Yandow DR, Meyer CA (June 2012). "Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection". AJR American Journal of Roentgenology 198 (6): W555–61.  
  3. ^ Hughes WT (1996). "Pneumocystis Carinii". In Barron S; et al. Barron's Medical Microbiology (4th ed.). University of Texas Medical Branch.  
  4. ^ "Supplementary Information: Microscopic appearance of Pneumocystis jiroveci from bronchial washings". Retrieved 5 June 2009. 
  5. ^ Medrano FJ, Montes-Cano M, Conde M, et al. (February 2005). in general population"Pneumocystis jirovecii". Emerging Infect. Dis. 11 (2): 245–50.  
  6. ^ Stern A, Green H, Paul M, Vidal L, Leibovici L (October 2014). "Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients". Cochrane Database Syst Rev 10 (CD005590).  
  7. ^ Ryan KJ; Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill.  
  8. ^ Puzio J, Kucewicz E, Sioła M, et al. (2009). "[Atypical and opportunistic pulmonary infections after cardiac surgery.]". Anestezjologia Intensywna Terapia (in Polish) 41 (1): 41–5.  
  9. ^ a b Morris A, Lundgren JD, Masur H, et al. (October 2004). "Current epidemiology of Pneumocystis pneumonia". Emerging Infect. Dis. 10 (10): 1713–20.  
  10. ^ Ponce CA, Gallo M, Bustamante R, Vargas SL (2010). "Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population". Clin Infect Dis 50 (3): 347–353.  
  11. ^ Schmoldt S, Schuhegger R, Wendler T, et al. (March 2008). transmission among 16 patients after kidney transplantation"Pneumocystis jirovecii"Molecular evidence of nosocomial . J. Clin. Microbiol. 46 (3): 966–71.  
  12. ^ Morris A, Beard CB, Huang L (January 2002). "Update on the epidemiology and transmission of Pneumocystis carinii". Microbes Infect. 4 (1): 95–103.  
  13. ^ de Boer M, Bruijnesteijn van Coppenraet L, Gaasbeek A, et al. (2007). "An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant  
  14. ^ Fannin S, Gottlieb MS, Weisman JD, et al. (1982). pneumonia among homosexual male residents of Los Angeles and Range Counties, California"Pneumocystis carinii"A Cluster of Kaposi's Sarcoma and . MMWR Weekly 31 (32): 305–7. 
  15. ^ Masur H, Michelis MA, Greene JB, et al. (10 December 1981). "An outbreak of community-acquired Pneumocystis carinii pneumonia". N Engl J Med 305 (24): 1431–8.  
  16. ^ a b c d  
  17. ^ Stringer JR, Beard CB, Miller RF, Wakefield AE (September 2002). ) for Pneumocystis from humans"Pneumocystis jiroveci"A new name (. Emerging Infect. Dis. 8 (9): 891–6.  
  18. ^ Cushion MT (1998). "Ch. 34: Pneumocystis carinii". In Collier, L.; Balows, A.; Sussman, M. Topley and Wilson's Microbiology and Microbial Infections (9th ed.). New York: Arnold and Oxford Press. pp. 645–683. 
  19. ^ Cushion MT (1998). "Taxonomy, genetic organization, and life cycle of Pneumocystis carinii". Semin. Respir. Infect 13 (4): 304–312.  
  20. ^ Cushion MT (2004). "Pneumocystis: unraveling the cloak of obscurity". Trends Microbiol 12 (5): 243–9.  
  21. ^ Stringer, James R.; Beard, Charles B.; Miller, Robert F.; Wakefield, Ann E. (Sep 2002). "A New Name for Pneumocystis from Humans and New Perspectives on the Host-Pathogen Relationship". Emerg Infect Dis 8: 891–896.  


Regarding nomenclature, when the name of Pneumocystis pneumonia (PCP) changed from P. carinii pneumonia to P. jirovecii pneumonia, it was at first felt that "PJP" should replace "PCP". However, because the term PCP was already used among physicians that managed patients with Pneumocystis infection, it was rationalized that the term PCP could continue to be used, as it could stand for PneumoCystis (jirovecii) Pneumonia.[21]

The older species name Pneumocystis carinii (which now applies only to the Pneumocystis species that is found in rats[17]) is still in common usage. As a result, Pneumocystis pneumonia (PCP) is also known as Pneumocystis jiroveci[i] pneumonia and (incorrectly) as Pneumocystis carinii pneumonia.[18][19][20]

Both Pneumocystis pneumonia and pneumocystis pneumonia[16] are orthographically correct; one uses the genus name per se and the other uses the common noun based on it. (This is the same reason, for example, why "group A Streptococcus" and "group A streptococcus" are both valid.) Synonyms for PCP include pneumocystosis[16] (pneumocystis + -osis), pneumocystiasis[16] (pneumocystis + -iasis), and interstitial plasma cell pneumonia.[16]


Prior to the development of more effective treatments, PCP was a common and rapid cause of death in persons living with AIDS. Much of the incidence of PCP has been reduced by instituting a standard practice of using oral co-trimoxazole (Bactrim / Septra) to prevent the disease in people with CD4 counts less than 200/μL. In populations that do not have access to preventive treatment, PCP continues to be a major cause of death in AIDS.

Since the start of the pentamidine, was the first clue to the existence of AIDS in the early 1980s.[14][15]


[13], it was suggested as likely, but not proven, that human-to-human spread may have occurred.Leiden For example, in one outbreak of 12 cases among transplant patients in [12][11] was originally described as a rare cause of Pneumocystis jirovecii


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.